SMS Pharmaceuticals has received a non?exclusive license through the Medicines Patent Pool (MPP) to manufacture molnupiravir, an investigational oral antiviral COVID?19 medicine, to increase broad access of treatment in 105 low? and middle? income countries (LMIC).
MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA., has entered into an agreement to license this pill for wider distribution with patent group. Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non? exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
SMS Pharmaceuticals is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state?of?the?art facilities.
